Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma
Status:
Recruiting
Trial end date:
2022-08-30
Target enrollment:
Participant gender:
Summary
This is a Phase 1, multi-center, open-label study of TRPH-222 monotherapy in subjects with
relapsed and/or refractory B-cell NHL. The study will be conducted in two Stages:
Dose-Escalation, Dose-Expansion.